Omnicell, Inc. — Q2 2011 Form 10-Q
Reporting period: Three and six months ended June 30, 2011; filed August 5, 2011. Amounts below are in U.S. dollars. Omnicell provides automated medication and medical-supply dispensing systems and related services, primarily to U.S. healthcare facilities.
Financial performance
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Revenue | $61.0 million | $54.7 million | $118.2 million | $108.9 million |
| Product revenue | $46.2 million | $42.0 million | $88.8 million | $84.3 million |
| Services and other revenue | $14.8 million | $12.7 million | $29.4 million | $24.5 million |
| Gross profit / margin | $33.8 million / 55.4% | $28.9 million / 52.8% | $65.5 million / 55.4% | $56.5 million / 51.8% |
| Operating income / margin | $4.2 million / 6.9% | $3.5 million / 6.4% | $5.3 million / 4.5% | $5.0 million / 4.6% |
| Net income | $2.6 million | $2.0 million | $3.3 million | $2.9 million |
| Diluted earnings per share | $0.08 | $0.06 | $0.10 | $0.09 |
- Q2 revenue increased 11.5% year over year; first-half revenue rose 8.6%. Service revenue growth reflected the expanding installed base, while product revenue depended on customer installation schedules.
- Q2 gross margin improved year over year. First-half gross margin rose, but operating margin was slightly lower as operating expenses grew faster than revenue.
- First-half operating cash flow was $7.3 million, down from $13.6 million. The company attributed the decline mainly to an $8.4 million year-over-year cash-flow impact from inventory changes and lower cash flow from receivables.
- Cash and cash equivalents were $181.3 million at June 30, 2011, versus $175.6 million at year-end 2010; the $8.1 million short-term investment held at year-end matured in June. The filing shows no debt balance. Management said cash and operating cash flow should cover anticipated working capital and capital expenditure needs for at least 12 months.
- First-half investing cash flow was positive $0.2 million, including proceeds from investment maturities; financing cash flow was negative $1.9 million, including $8.0 million of share repurchases.
Changes, outlook and notable items
- Management forecast 2011 total revenue growth of 8%–10%. It expected service gross profit to remain consistent and SG&A to remain consistent in absolute dollars for the rest of 2011; it expected R&D spending to increase as the business grows. No EPS guidance was provided in the filing text.
- Product gross profit benefited from lower material costs and product mix; service gross profit rose as revenue from the larger installed base grew without a proportional increase in costs. Management cautioned that margins may fluctuate with product mix, installation levels and service staffing.
- Inventory increased to $17.4 million from $9.8 million at December 31, 2010, including a build for the G4 platform transition. Management expected inventory to decline during 2011 as production of the new computer console shifted to suppliers in China.
- SG&A increased 19% in Q2 and 19.4% in the first half, reflecting higher sales and marketing compensation and other costs. First-half SG&A also included a $1.0 million Medacist settlement charge and related legal costs. The May 2011 settlement resolved pending litigation in exchange for a perpetual patent license; an additional $0.5 million transfer fee may be payable if specified change-in-control conditions occur.
- Omnicell repurchased 559,175 shares during the first half for $8.0 million; $16.9 million remained authorized. It reported 33,134,997 common shares outstanding as of August 1, 2011.
- Revenue is generally recognized upon installation, which may occur weeks to a year or more after order. The company adopted new multiple-deliverable revenue guidance prospectively in 2011; adoption had no material effect to date, but future effects were described as unpredictable.
- Disclosure controls were not effective at June 30, 2011 because remediation of a material weakness in income-tax accounting controls was incomplete. Management described corrective steps, including enhanced tax consultant review, a Senior Tax Manager search and tax software implementation, and stated it believed the financial statements fairly presented the company’s position and results.
Key risks and contingencies
- Customer capital-budget constraints, economic conditions and healthcare-policy uncertainty may delay or reduce orders. Installation delays can defer revenue recognition, and quarterly results can fluctuate with order mix and installation timing.
- Competition, product acceptance and successful launch and integration of new products—including the G4 platform—could affect growth and margins. The company also cited reliance on certain limited-source suppliers and the need to manage inventory effectively.
- The tax-accounting material weakness remains a reporting and investor-confidence risk until remediation is completed. The filing also identifies risks relating to tax estimates, customer credit, healthcare regulation, product liability, intellectual property and international operations.
- Contractual obligations at June 30 totaled $9.8 million, principally operating leases and supplier/contract-manufacturer commitments; no material change in contractual obligations was reported. The company reported no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether revenue growth and planned 8%–10% full-year growth are supported by orders and timely customer installations.
- Whether inventory declines as planned after the G4 production transition, and whether the build creates any obsolescence or margin risk.
- Whether operating cash flow recovers from the first-half decline and how working-capital needs evolve.
- Progress in remediating the income-tax control material weakness and any related financial-statement adjustments.
- Whether the Medacist settlement’s contingent $0.5 million transfer fee is triggered and whether other significant legal or contingency developments arise.